TerminatedPhase 2

Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

Stopped: PI left the institution

United States5 participantsStarted 2013-01

Plain-language summary

This phase II trial studies how well romiplostim works in increasing low platelet counts in patients with multiple myeloma receiving chemotherapy. Romiplostim may cause the body to make platelets after chemotherapy

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Plasmacytomas on tissue biopsy
. Bone marrow plasmacytosis (\> 30% plasma cells)
. Monoclonal immunoglobulin spike on serum electrophoresis (immunoglobin G \[IgG\] \> 3.5 G/dL or immunoglobin A \[IgA\] \> 2.0 G/dL) or kappa or lambda light chain excretion \> 1 G/day on 24 hour urine protein electrophoresis
. Bone marrow plasmacytosis (10 to 30% plasma cells)
. Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria
. Lytic bone lesions
. Normal immunoglobin M (IgM) \< 50 mg/dL, IgA \< 100 mg/dL, or IgG \< 600 mg/dL

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Percentage of Patients Who Have Responded

Timeframe: 8 weeks

Trial details

NCT IDNCT01676961

SponsorNYU Langone Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-11

Results submitted2017-08-03

View on ClinicalTrials.gov More Refractory Multiple Myeloma trials